VITAMIN D RECEPTOR ACTIVATOR AND DIETARY SODIUM RESTRICTION TO REDUCE RESIDUAL URINARY ALBUMIN EXCRETION IN CHRONIC KIDNEY DISEASE ( VIRTUE STUDY ) : RATIONALE AND STUDY PROTOCOL 2 A

[1]  D. Bolignano,et al.  Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial , 2014, Hypertension.

[2]  S. Yusuf,et al.  The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial , 2014, European journal of preventive cardiology.

[3]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[4]  Toshiyuki Shimizu,et al.  A nonclassical vitamin D receptor pathway suppresses renal fibrosis. , 2013, The Journal of clinical investigation.

[5]  M. D. de Borst,et al.  Active vitamin D treatment for reduction of residual proteinuria: a systematic review. , 2013, Journal of the American Society of Nephrology : JASN.

[6]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[7]  H. Parving,et al.  Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. , 2012, Kidney international.

[8]  S. Solomon,et al.  Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.

[9]  J. Luther.  Sodium intake, ACE inhibition, and progression to ESRD. , 2012, Journal of the American Society of Nephrology : JASN.

[10]  G. Navis,et al.  Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[11]  G. Navis,et al.  Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial , 2011, BMJ : British Medical Journal.

[12]  P. Hopkins,et al.  25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians , 2011, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[13]  G. Navis,et al.  Vitamin D in chronic kidney disease: new potential for intervention. , 2011, Current drug targets.

[14]  H. Parving,et al.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial , 2010, The Lancet.

[15]  D. Deb,et al.  Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. , 2010, Journal of the American Society of Nephrology : JASN.

[16]  Robert R. Quinn,et al.  Relation between kidney function, proteinuria, and adverse outcomes. , 2010, JAMA.

[17]  S. Fishbane,et al.  Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  I. D. de Boer.  Vitamin D and glucose metabolism in chronic kidney disease , 2008, Current opinion in nephrology and hypertension.

[19]  R. Light,et al.  Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial , 2008, Hypertension.

[20]  G. Navis,et al.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.

[21]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[22]  Wei Zheng,et al.  1,25-Dihydroxyvitamin D3 Suppresses Renin Gene Transcription by Blocking the Activity of the Cyclic AMP Response Element in the Renin Gene Promoter* , 2007, Journal of Biological Chemistry.

[23]  B. Brenner,et al.  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. , 2007, Journal of the American Society of Nephrology : JASN.

[24]  R. Henning,et al.  Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. , 2003, Kidney international.

[25]  C. Schmid,et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.

[26]  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) , 1997, Lancet.

[27]  A. Donker,et al.  Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran. , 1996, Journal of the American Society of Nephrology : JASN.

[28]  F. Locatelli,et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.

[29]  D. de Zeeuw,et al.  Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. , 1994, Kidney international. Supplement.

[30]  D. de Zeeuw,et al.  Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. , 1989, Kidney international.

[31]  L. Arisz,et al.  The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. , 2009, Acta medica Scandinavica.